Log In
Print
BCIQ
Print
Print this Print this
 

Rencarex, girentuximab (formerly WX-G250)

  Manage Alerts
Collapse Summary General Information
Company Wilex AG
DescriptionChimeric mAb against carbonic anhydrase IX (CAIX)
Molecular Target Carbonic anhydrase IX (CAIX)
Mechanism of ActionAntibody dependent cellular cytotoxicity (ADCC)
Latest Stage of DevelopmentPhase III
IndicationRenal cancer
Partner

Esteve S.A.; Nestle S.A.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today